

MANULIFE DANA EKUITAS TEKNOLOGI KESEHATAN GLOBAL DOLAR

SEP 2022


Investment Objective

To achieve long term capital growth by investing mainly in equity securities of companies which predominant economic activities are in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology sectors, onshore and/or offshore, directly and/or through mutual fund(s).


Fund Information

Inception Date	: 18 Oct 21
Fund Size	: USD 4,001,724.89
Fund Currency	: USD
Type of fund	: Equity
Valuation	: Daily
Custodian Bank	: Bank DBS Indonesia
Annual Management Fee	: 2.50%
Net Asset Value/Unit ³⁾	: USD 0.9081
Bloomberg Code	: MATKGMU IJ

Performance Since Inception




Monthly Performance Last 3 Years



Risk Classification

Risk classification is based on type of fund.



Allocation

Equity	: 80 - 100 %
Money Market	: 0 - 20 %

Portfolio

Equity Onshore	: 0.00%
Equity Offshore	: 98.49%
Money Market	: 1.51%

Top 5 Holdings

1 BlackRock World Healthscience Fund D2 USD

Fund Performance

Performance in USD per (30/09/22)							
	1 mo	3 mo	6 mo	YTD	1 yr	3 yr ¹⁾	5 yr ¹⁾
MANTKG	-3.38%	-5.46%	-11.79%	-13.83%	n/a	n/a	n/a
BM ²⁾	-3.94%	-6.78%	-13.49%	-16.64%	N/A	n/a	n/a

Yearly Performance							
	2021	2020	2019	2018	2017	2016	2015
MANTKG	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BM ²⁾	n/a	n/a	n/a	n/a	n/a	n/a	n/a

Note

- 1) Annualized (1 year = 365 days) and using compound method (for products that have been more than one year old since inception).
- 2) The benchmark is MSCI World Health Care Index.
- 3) The Net Asset Value / Unit has calculated the costs, including fees related to transaction and transaction settlement as well as administration and recording.

Investment Manager Commentary

Global equity market was volatile in September. The Fed's monetary policy was a key focus after Fed Chair Jerome Powell affirms The Fed's priority is to tackle inflation even as growth is expected to run below trend. The Fed revised its terminal rate expectation to 4.6% from previous expectation 3.8% while growth forecast revised down for 2022 and 2023. This statement was not well received by the market that expected The Fed could pivot to be more dovish in 2023. With monetary policy uncertainty and geopolitical condition, we expect continued market volatility. However we are encouraged by the health care's sector relative resilience compared to the broader equity index. We seek opportunities in segments with attractive valuations, stable growth, and promising product pipelines over the medium to long term. We also consider new innovations and technological developments in the biotechnology, pharmaceuticals, and medical devices space.

Disclaimer: This report is prepared by PT Asuransi Jiwa Manulife Indonesia only for information purposes and not to be used as a sales offering or proposal. Although this report has been prepared meticulously, PT Asuransi Jiwa Manulife Indonesia does not guarantee its accuracy, sufficiency or completeness, and is not responsible for any consequences arising from any actions which are based on the information stated herein. Investments in capital market instruments are subject to various risks which include, but not limited to, market risk, credit risk, interest rate risk, exchange rate risk (particularly in Fund which has allocation in offshore investment instruments in different currencies than the Fund's currency), liquidity risk and other risks which could result in performance volatility. Therefore, the performance of this Fund is not guaranteed, the unit price of each Fund may go up or down and past performance does not necessarily indicate of future performance.

Manulife Indonesia

Established in 1985, PT Asuransi Jiwa Manulife Indonesia (Manulife Indonesia) is part of Manulife Financial Corporation Group, a Canadian financial services group that operates in Asia, Canada and the United States. Manulife Indonesia offers a wide range of financial services, including life insurance, accident and health insurance, investment and pension plans to individual customers and group clients in Indonesia. Through a network of almost 11,000 employees and professional agents spread across more than 25 sales offices, Manulife Indonesia serves more than 2 million customers in Indonesia.

PT Asuransi Jiwa Manulife Indonesia is registered and supervised by the Otoritas Jasa Keuangan (OJK). To learn more about Manulife Indonesia, follow us on Facebook, Twitter, Instagram, YouTube, or visit

